Understanding the biology of relapsed ependymoma brain tumours to help improve treatments
Deciphering the New Molecular Landscape in Paediatric Recurrent Ependymoma: Implications for Molecular Targeted Therapy
Improving our understanding of immunotherapy in high-risk neuroblastoma
Understanding and improving the mechanism of action of anti-GD2 monoclonal antibody therapy in neuroblastoma
Stopping ‘cut-and-run’ DNA errors to help treat leukaemia and predict relapse
Towards inhibiting cut-and-run: An aberrant V(D)J recombination reaction that leads to lymphoid cancers
Next generation molecular profiling of malignant rhabdoid tumours
Identifying which are the cellular molecules that drive growth and spread of rhabdoid tumours, and to use this information to nominate new treatment strategies and develop real-time diagnostic tests for personalising treatment
Improving the outlook for children with Philadelphia positive ALL
Unravelling clinical heterogeneity in Philadelphia positive ALL
Mapping drug targets in aggressive non-Hodgkin lymphoma
Investigation of potential therapeutic targets in paediatric aggressive B-cell non-Hodgkin lymphoma - towards kinder, more effective treatments
"Getting it right first time" for children with renal tumours
Improving prediction of relapse, treatment delivery and outcomes for children with renal tumours in the UK
Using digital technology to improve our understanding of rhabdomyosarcoma
Deep learning: An integrated approach to define clinical significance to components of the tumour microenvironment of rhabdomyosarcomas
Investigating the genetic pathways that control leukaemia growth
RNA helicase DDX3X regulates JAK-STAT signalling in acute lymphoblastic leukaemia